Recurrent Non-small Cell Lung Cancer Recruiting Phase 2 Trials for Ponatinib (DB08901)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01935336Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersTreatment